BA
TBPH icon

BlackRock Advisors’s Theravance Biopharma TBPH Stock Holding History

BlackRock Advisors’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$683K Buy
21,411
+2,480
+13% +$76.9K ﹤0.01% 2042
2016
Q3 		$686K Buy
18,931
+3,012
+19% +$83.9K ﹤0.01% 2015
2016
Q2 		$361K Buy
15,919
+2,886
+22% +$62.3K ﹤0.01% 2287
2016
Q1 		$245K Buy
13,033
+893
+7% +$14.6K ﹤0.01% 2457
2015
Q4 		$199K Sell
12,140
-4,037
-25% -$64.1K ﹤0.01% 2574
2015
Q3 		$178K Sell
16,177
-572
-3% -$7.28K ﹤0.01% 2790
2015
Q2 		$218K Buy
16,749
+1,339
+9% +$20.8K ﹤0.01% 2747
2015
Q1 		$267K Buy
15,410
+2,427
+19% +$44.5K ﹤0.01% 2512
2014
Q4 		$194K Sell
12,983
-650
-5% -$11.3K ﹤0.01% 2643
2014
Q3 		$314K Sell
13,633
-298
-2% -$8.65K ﹤0.01% 2317
2014
Q2 		$444K Buy
+13,931
New +$419K ﹤0.01% 2098

Other funds holding TBPH

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock Advisors's TBPH Position: Q4 2016 in Review

BlackRock Advisors increased its Theravance Biopharma (TBPH) stake by 13% in Q4 2016, buying an estimated $76.9K and bringing the position to 21,411 shares worth $683K. The position accounts for ﹤0.01% of the portfolio, ranked #2042.

BlackRock Advisors first reported a position in TBPH in Q2 2014 and has held it in 11 quarters since. The position peaked at $686K in Q3 2016. 98 funds tracked by Wall St. Rank hold TBPH as of Q4 2016.

  • BlackRock Advisors held 21,411 shares of Theravance Biopharma worth $683K as of Q4 2016.
  • BlackRock Advisors bought 2,480 Theravance Biopharma shares in Q4 2016, an estimated $76.9K.
  • Theravance Biopharma made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #2042 holding.
  • BlackRock Advisors first reported a position in Theravance Biopharma in Q2 2014 and has held it in 11 quarters since.
  • BlackRock Advisors's Theravance Biopharma position peaked at $686K in Q3 2016.
  • 98 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.